Inhalation, deposition, and fate of insulin and other therapeutic proteins

被引:52
作者
Brain, Joseph D. [1 ]
机构
[1] Harvard Univ, Sch Publ Hlth, Mol & Integrat Physiol Sci Program, Dept Environm Hlth, Boston, MA 02115 USA
关键词
D O I
10.1089/dia.2007.0228
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In contrast to other interfaces between the outer and inner environment, such as the skin and gastrointestinal tract, the lungs are ideally suited for the delivery of polypeptides and proteins to the systemic circulation. There is a wealth of experience from aerosol physics and lung biology to support the idea that insulin delivery via the lungs is an effective strategy. The elaborate branching network of airways, the extensive surface area of the deep lung, and the thin air-blood barrier make it possible to deliver insulin and other proteins to the parenchyma, where it can be absorbed into the pulmonary circulation and become available throughout the body. Protein-containing aerosols in inspired air deposit throughout the respiratory tract because of the following forces: gravity, diffusion, and inertial impaction. Lung anatomy, breathing pattern, and particle size determine the influence of these forces. Once deposited in the lungs, most protein-containing formulations quickly dissolve in airway or alveolar lining fluid. Then, a significant fraction of insulin is transported across the air-blood barrier into the blood, where it continues to be biologically active. A substantial fraction-usually the majority-is cleared from the lungs or degraded within the lungs.
引用
收藏
页码:S4 / S15
页数:12
相关论文
共 35 条
[11]   IDENTIFICATION OF THE METAL ASSOCIATED WITH THE INSULIN DEGRADING ENZYME [J].
EBRAHIM, A ;
HAMEL, FG ;
BENNETT, RG ;
DUCKWORTH, WC .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 181 (03) :1398-1406
[12]   Protein drug stability: A formulation challenge [J].
Frokjaer, S ;
Otzen, DE .
NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (04) :298-306
[13]  
GANNSLEN M, 1925, KLIN WOCHENSCHR, V4, P71
[14]   Systemic delivery of drugs to humans via inhalation [J].
Gonda, I .
JOURNAL OF AEROSOL MEDICINE-DEPOSITION CLEARANCE AND EFFECTS IN THE LUNG, 2006, 19 (01) :47-53
[15]   Fundamentals of pulmonary drug delivery [J].
Groneberg, DA ;
Witt, C ;
Wagner, U ;
Chung, KF ;
Fischer, A .
RESPIRATORY MEDICINE, 2003, 97 (04) :382-387
[16]   Regulation of multicatalytic enzyme activity by insulin and the insulin and the insulin-degrading enzyme [J].
Hamel, FG ;
Bennett, RG ;
Duckworth, WC .
ENDOCRINOLOGY, 1998, 139 (10) :4061-4066
[17]   Intrapulmonary administration of insulin to healthy volunteers [J].
Jendle, JH ;
Karlberg, BE .
JOURNAL OF INTERNAL MEDICINE, 1996, 240 (02) :93-98
[18]   Glycemic control from 1988 to 2000 among U.S adults diagnosed with type 2 diabetes - A preliminary report [J].
Koro, CE ;
Boialin, SJ ;
Bourgeois, N ;
Fedder, DO .
DIABETES CARE, 2004, 27 (01) :17-20
[19]   Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications [J].
Labiris, NR ;
Dolovich, MB .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 56 (06) :600-612
[20]   Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications [J].
Labiris, NR ;
Dolovich, MB .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 56 (06) :588-599